NeOnc Technologies Holdings is trading sharply higher on August 14, 2026, after positive Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study reportedly met its primary endpoint, with six-month progression-free survival of 48.9% versus a 20% benchmark and statistical significance of p=0.0047.
- Trading at $3.86 (+20.11%).
- Trading activity is elevated at 387.93K shares versus a 303.37K daily average.
- The August 12 data readout and investor call provided the immediate catalyst.